{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:43:24Z","timestamp":1792899804849,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072265"],"award-info":[{"award-number":["82072265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["B2021302"],"award-info":[{"award-number":["B2021302"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.virusres.2021.198453","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:41:08Z","timestamp":1620819668000},"page":"198453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-9101","authenticated-orcid":false,"given":"Haohui","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2021.198453_bib0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2015.03.022","article-title":"Viral quasispecies","volume":"479-480","author":"Andino","year":"2015","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.virusres.2021.198453_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.virusres.2021.198453_bib0015","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/jmv.25078","article-title":"Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China","volume":"90","author":"Deng","year":"2018","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.virusres.2021.198453_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3851\/IMP3345","article-title":"Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women","volume":"25","author":"Deng","year":"2020","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.virusres.2021.198453_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"5","key":"10.1016\/j.virusres.2021.198453_bib0030","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"EASL","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virusres.2021.198453_bib0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.virusres.2021.198453_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13109","article-title":"Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience","volume":"31","author":"Ikegami","year":"2017","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.virusres.2021.198453_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2016.10.013","article-title":"Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3\/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine","volume":"137","author":"Ikram","year":"2017","journal-title":"Antiviral. Res."},{"issue":"10","key":"10.1016\/j.virusres.2021.198453_bib0050","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1128\/AAC.03466-14","article-title":"Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV\/HIV coinfection","volume":"58","author":"Jabara","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.virusres.2021.198453_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2334-13-61","article-title":"Analysis of HCV quasispecies dynamic under selective pressure of combined therapy","volume":"13","author":"Jardim","year":"2013","journal-title":"Bmc. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virusres.2021.198453_bib0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.virusres.2021.198453_bib0065","doi-asserted-by":"crossref","first-page":"e1000304","DOI":"10.1371\/journal.pgen.1000304","article-title":"The population genetics of dN\/dS","volume":"4","author":"Kryazhimskiy","year":"2008","journal-title":"PLoS. Genet."},{"issue":"2","key":"10.1016\/j.virusres.2021.198453_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.virusres.2021.198453_bib0075","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gut.2010.226225","article-title":"Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy","volume":"60","author":"Liu","year":"2011","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.virusres.2021.198453_bib0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.virusres.2021.198453_bib0085","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1872-034X.2008.00320.x","article-title":"HCV selection and HVR1 evolution in a chimpanzee chronically infected with HCV-1 over 12 years","volume":"38","author":"Lu","year":"2008","journal-title":"Hepatol. Res."},{"issue":"23","key":"10.1016\/j.virusres.2021.198453_bib0090","doi-asserted-by":"crossref","first-page":"12541","DOI":"10.1128\/JVI.00826-13","article-title":"Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression","volume":"87","author":"Miura","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2021.198453_bib0095","first-page":"113","article-title":"Hepatitis C virus proteins: from structure to function","volume":"369","author":"Moradpour","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.virusres.2021.198453_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents. Chemother."},{"issue":"1","key":"10.1016\/j.virusres.2021.198453_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01620-17","article-title":"In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3\/4A Protease Inhibitor Glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents. Chemother."},{"issue":"5","key":"10.1016\/j.virusres.2021.198453_bib0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virusres.2021.198453_bib0115","doi-asserted-by":"crossref","first-page":"853076","DOI":"10.1155\/2014\/853076","article-title":"Comparison of quasispecies diversity of HCV between chronic hepatitis c and hepatocellular carcinoma by Ultradeep pyrosequencing","volume":"2014","author":"Park","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.virusres.2021.198453_bib0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jvh.13208","article-title":"Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis","volume":"27","author":"Rao","year":"2020","journal-title":"J. Viral. Hepat."},{"issue":"7","key":"10.1016\/j.virusres.2021.198453_bib0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4254\/wjh.v6.i7.520","article-title":"Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C","volume":"6","author":"Rao","year":"2014","journal-title":"World. J. Hepatol."},{"issue":"10207","key":"10.1016\/j.virusres.2021.198453_bib0130","first-page":"1451","volume":"394","author":"Spearman","year":"2019","journal-title":"Hepatitis C. Lancet"},{"issue":"1","key":"10.1016\/j.virusres.2021.198453_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"Suda","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.virusres.2021.198453_bib0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/genetics\/123.3.585","article-title":"Statistical method for testing the neutral mutation hypothesis by DNA polymorphism","volume":"123","author":"Tajima","year":"1989","journal-title":"Genetics"},{"issue":"9","key":"10.1016\/j.virusres.2021.198453_bib0145","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"issue":"2","key":"10.1016\/j.virusres.2021.198453_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.virusres.2021.198453_bib0155","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/jgh.13379","article-title":"A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin","volume":"31","author":"Wei","year":"2016","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016817022100160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016817022100160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:33:29Z","timestamp":1779150809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016817022100160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":31,"alternative-id":["S016817022100160X"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2021.198453","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2021.198453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"198453"}}